Clinical trials generate more data from more sources than ever before, yet greater data availability has not automatically translated into faster development. Clinical leaders and heads of data management must contend with increasingly complex protocols, fragmented data flows, manual transcription, disconnected handoffs and the operational burden of collecting information that may not directly support study objectives. With non-EDC sources now representing the majority of study inputs, traditional electronic data capture alone can no longer provide the speed, flexibility or connectivity required by today’s trials.

This white paper explores how study-specific criticality and Digital-First Clinical Data Collection can help sponsors address these challenges. Rather than eliminating EDC, the approach reduces unnecessary dependency on it by determining which endpoints and data sources are genuinely relevant, reliable, nonduplicative, harmonized and timely. It then prioritizes direct-from-source collection across technologies including eConsent, eCOA, IRT, eSource, connected devices, laboratories and ECG. The result is a more purposeful data strategy that reduces duplication, limits downstream friction and enables trusted data to move more rapidly into review, monitoring and analytics.

Discover how IQVIA brings these elements together within a unified, real-time data ecosystem that connects patient and operational data through a shared data store. The paper explains why the greatest opportunity for acceleration begins before study execution, when endpoint strategy, critical-to-quality factors and data-source selection can still be shaped. By anticipating bottlenecks, minimizing unnecessary EDC collection and enabling near-real-time data flow, sponsors can support earlier, better-informed decisions and pursue faster, more predictable clinical development from study design through delivery.